stoxline Quote Chart Rank Option Currency Glossary
NanoViricides, Inc. (NNVC)
2.58  0.13 (5.31%)    06-13 16:00
Open: 2.49
High: 2.77
Volume: 524,699
Pre. Close: 2.45
Low: 2.48
Market Cap: 30(M)
Technical analysis
2024-06-13 4:45:10 PM
Short term     
Mid term     
Targets 6-month :  4.19 1-year :  4.89
Resists First :  3.58 Second :  4.19
Pivot price 2.52
Supports First :  2.33 Second :  1.55
MAs MA(5) :  2.8 MA(20) :  2.43
MA(100) :  1.48 MA(250) :  1.34
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  48 D(3) :  59.3
RSI RSI(14): 56.2
52-week High :  3.58 Low :  1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NNVC ] has closed below upper band by 45.2%. Bollinger Bands are 145.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.77 - 2.78 2.78 - 2.79
Low: 2.46 - 2.47 2.47 - 2.49
Close: 2.56 - 2.58 2.58 - 2.6
Company Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Headline News

Mon, 10 Jun 2024 Begins Coverage on NanoViricides (NYSE:NNVC) - Defense World

Tue, 14 May 2024
NanoViricides shares gain as new data shows lead drug asset's strong activity against RSV - Proactive Investors USA

Mon, 13 May 2024
NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential - Proactive Investors USA

Wed, 08 May 2024
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox - Miami Herald

Tue, 30 Apr 2024
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer

Thu, 14 Mar 2024
NanoViricides (NASDAQ: NNVC) Hits Key Milestones For Its Virus-Fighting Drug Candidate NV-387 In 2023; Mo - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 12 (M)
Shares Float 11 (M)
Held by Insiders 4.6 (%)
Held by Institutions 10.1 (%)
Shares Short 317 (K)
Shares Short P.Month 273 (K)
Stock Financials
EPS -0.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.1
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -31.2 %
Return on Equity (ttm) -52.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.74
Qtrly Earnings Growth 0 %
Operating Cash Flow -6 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -3.36
PEG Ratio 0
Price to Book value 2.34
Price to Sales 0
Price to Cash Flow -5.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android